Clinical study

Researchers are exploring whether transferring younger gut microbiomes could slow aging and prevent age-related diseases. If validated, the work could point to microbiome-based therapies that affect systemic health,...

Researchers are using a new MRI-based index (ANDI) to look for early brain changes linked to Parkinson’s disease and dementia in groups at higher risk, including people with inflammatory bowel disease. If successful, the...

A simple home test for urinary oxalate and Ox/Crea ratio could make monitoring more practical than 24-hour urine collections, helping prevent stone recurrence and allowing earlier treatment adjustments for people at...

This study suggests brain glymphatic function — a fluid-clearance system — may be altered in people with Crohn’s disease and could relate to inflammation and common neuropsychiatric symptoms like fatigue, anxiety,...

Many people on ustekinumab who lose response wonder whether increasing dosing frequency helps. This prospective study suggests that empiric intensification to every 4 or 6 weeks raised drug levels and was linked with...

The study reports a targeted nanoparticle designed to deliver celastrol selectively to inflamed intestinal tissue and colorectal tumors, which could—if translated successfully—address limitations of oral celastrol and...

Patients with ulcerative colitis and PSC face higher risk of pouch inflammation after IPAA. The study reports fewer pouchitis events among the small group who received antibiotics or immunosuppression, which could...

IBD increases risk of osteoporosis; identifying blood proteins that predict later bone loss could help flag higher-risk patients and reveal biological links between gut inflammation and bone health.

The study identifies a cellular mechanism (JAK1-STAT6 pathway) by which upadacitinib can lower IL13RA2 — a molecule tied to inflammation and anti-TNF resistance — which could help explain how JAK inhibitors work in IBD...

If confirmed, a gut-derived strain of Lancefieldella parvula that rises with local inflammation could become a mucosal biomarker to help track disease severity or study inflammation mechanisms in IBD.

If intestinal ultrasound shows mild isolated hyperemia even with normal bowel wall thickness, this study found a higher chance of treatment changes, steroid use, surgery, or hospitalization within a year — information...

This study highlights changing patterns of IBD presentation and treatment over 26 years in a large Hispanic cohort, which may affect outcomes and access-to-care discussions for Hispanic patients.

Fatigue is common and disabling for people with IBD; this study shows that factors beyond intestinal inflammation—especially central sensitization and psychological symptoms—explain much of fatigue. That means treating...

1) People with IBD are known to have higher cardiovascular risk; this study directly assessed subclinical carotid atherosclerosis to see if plaque burden explains that risk.

Ustekinumab is already approved for moderate-to-severe Crohn's disease; this real-world study reports encouraging longer-term clinical, biological, and endoscopic outcomes up to 96 weeks and suggests good treatment...

The review links gut microbiota changes and mucosal immune responses across IBD and IgA nephropathy, suggesting that gut dysbiosis may contribute to systemic immune-driven disease.

Drug levels and how patients reach remission can differ depending on prior biologic use. For families and clinicians managing pediatric Crohn's, this can affect how infliximab dosing and monitoring are interpreted after...

The study points to a specific immune cell type (pro-inflammatory CD4+ macrophages) and altered cellular interactions in rectal tissue that are linked to perianal fistulizing Crohn's disease, which may help explain...

Better triage methods that combine FIT with demographics and blood biomarkers could reduce unnecessary colonoscopies while keeping sensitivity for colorectal cancer and other serious findings, which matters for...

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from gastroendonews.com.

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Research and clinical trials. The original article is from Corporate Philanthropy Report.

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Infliximab. The original article is from Journal of Genetic Engineering and...

Children with IBD often wait years for medicines to be approved after adult approvals; this review shows many ongoing paediatric trials for biologics and small molecules that could improve treatment options.

If dietary oxalate influences gut inflammation, it could be a modifiable dietary factor for some people with IBD and might help explain variability in symptoms. The study points to transporters as potential markers of...

IBD patients often face high psychological burden; knowing whether MBCT is acceptable and feasible helps patients and clinicians weigh it as a support option. Practical barriers (time, fatigue, disease activity) and...

Intestinal ultrasound is increasingly used to evaluate Crohn’s disease because it’s noninvasive, repeatable, and can detect activity and some complications—potentially reducing reliance on more invasive tests. Wider...

Smoking-related products may influence Crohn’s disease recurrence after surgery; patients and clinicians may want to be aware of new data comparing heat-not-burn tobacco and e-cigarette use to nonsmoking after ileocolic...

GLP-1 receptor agonists — drugs commonly used to treat obesity and metabolic disease — may help patients with IBD by reducing visceral fat and improving cardiometabolic health.

The study tests whether a simple blood-derived index (CRP×NLR) can help identify moderate-to-severe endoscopic inflammation when timely endoscopy is limited in hospitalized UC patients.

Identifies candidate drug‑level and immune biomarker cut‑points linked with endoscopic healing in pediatric Crohn's disease, which could help guide dosing or treatment changes if validated.

Non-invasive fecal lipid markers could help differentiate UC from CD and improve diagnostic molecular profiling in IBD if validated, which may be useful for patients and clinicians seeking less-invasive diagnostic tools.

GI infections—especially CMV—were common in this study and much more frequent in acute severe UC than in remission, suggesting testing for infections can change diagnosis and management during severe flares.

The study evaluates how well first-line 5-ASA therapy achieves modern treatment targets (endoscopic, histologic, and biomarker remission) in real-world UC patients who are clinically in remission. Patients and clinicians...

Micronutrient deficiencies are common in IBD and can worsen anemia, healing, and neurologic function. This study shows inpatient testing focuses on B12 while missing other commonly deficient nutrients (B1, B6, zinc),...

If confirmed, a brain perivascular/glymphatic change linked to intestinal inflammation could help explain why sleep problems are common in Crohn's disease and point to new research targets for symptom mechanisms and...

A targeted, pH-sensitive colon delivery system could improve effectiveness and reduce systemic side effects of drugs used for UC by releasing medication in the colon and protecting it from stomach degradation. For people...

Identifies gene and microbiome patterns linked to progression from inflammation to irreversible bowel fibrosis in Crohn’s disease, which could eventually help predict who is at higher risk and inform prevention...

Distinct circulating immune signatures could help differentiate active UC from CD and suggest disease-specific pathways that might guide future biomarkers or therapies.

If validated, blood microRNAs could become noninvasive biomarkers to help track inflammation and predict biochemical response to infliximab or vedolizumab in Crohn’s disease, complementing CRP and fecal calprotectin.

The work points to measurable molecular and microbial patterns that may help distinguish treatable inflammation from progressive fibrosis and suggests AI could aid in building predictive tools from limited samples —...

AI tools could make objective disease assessment faster and more consistent, help detect inflammation beyond what symptoms suggest, and ultimately support more personalized treatment choices for people with Crohn’s...

The study addresses a practical question for people with IBD: whether sequencing anti-TNF therapy after a biologic from a different class affects how well the anti-TNF works. Shorter durability — especially in ulcerative...

Patients with IBD commonly change or restrict their diets and often want reliable guidance. This study tested automated personalized feedback plus an online nutrition portal and found improved food-related quality of...

This correction updates duplicated data points and clarifies methods in a preclinical synthetic-biology study about engineered materials that secrete therapeutic proteins for IBD, which affects interpretation and...

The study suggests a probiotic strain (Lactobacillus plantarum) reduced inflammation and prolonged remission in multiple mouse models of Crohn’s-like disease, indicating microbiome-based approaches might be promising to...

Finding neutralising anti-IL-10 antibodies in a subset of children with IBD may help explain why some patients have more severe, treatment‑resistant disease and points to a potential biomarker for risk stratification.

AI could help make IBD assessments (endoscopy, histology, imaging, biomarkers) more objective and faster, which may improve monitoring, treatment selection, and early detection of complications for people with Crohn’s...

Researchers used genetics plus single-cell sequencing and ELISA to prioritize plasma protein ratios that may causally relate to ulcerative colitis. If validated in larger studies, such biomarkers could help with...